Heng Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Heng Liu has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Andrew V. Kossenkov
The Wistar Institute, Philadelphia, Pennsylvania
1 shared publication - Benjamin G. Bitler
Department of OB/GYN, The University of Colorado Anschutz Medical Campus, Aurora, Colorado
1 shared publication - Chen Wang
Peking University China–Japan Friendship School of Clinical Medicine, Beijing, China
1 shared publication - Dajiang Guo
Department of Anatomical and Cellular Pathology and State Key Laboratory of Translational Oncology Prince of Wales Hospital, The Chinese University of Hong Kong Shatin Hong Kong
1 shared publication - Iris Müller
Cell Biology Program and Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, USA
1 shared publication - Jianhuang Lin
Immunology, Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, Pennsylvania
1 shared publication
Latest Publications
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figures S1-S5 from The SETDB1–TRIM28 Complex Suppresses Antitumor Immunity
Supplementary Figures S1-S5 + Legends
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigures S1-S5 from The SETDB1–TRIM28 Complex Suppresses Antitumor Immunity
Supplementary Figures S1-S5 + Legends
- Open Access
- 26 July 2021
- Published by Wiley in Cancer Medicine
- Vol. 10 (18) , 6416-6427
DYRK1A activates NFATC1 to increase glioblastoma migration
Glioblastoma (GBM) is the most aggressive glioma, and is prone to develop resistance to chemotherapy and radiotherapy; hence, patients with glioblastoma have a high recurrence rate and a low 1‐year survival rate. In addition, the pathogenesis of glioblastoma is complex and largely unknown, and the available treatments are limited. Here, we uncovered a fundamental role of DYRK1A in regulating NFATC1 in GBMs. We found that DYRK1A was highly expressed in glioma and glioblastoma cells, and its expression was positively correlated with that of NFATC1. Moreover, inhibition of DYRK1A promoted NFATC1 degradation in GBM cells and sharply reduced the transactivation of NFATC1, not only by decreasing the expression of NFATC1‐targeted genes, but also by reducing the luciferase activity, and vice versa. However, DYRK1A had the opposite effect on NFATC2. Most importantly, our data suggest that DYRK1A inhibition reduces glioblastoma migration. Polypeptides derived from the DYRK1A‐targeted motif of NFATC1, by competitively blocking DYRK1A kinase activity on NFATC1, clearly destabilized NFATC1 protein and impaired glioblastoma migration. We propose that the recovery of NFATC1 stability is a key oncogenic event in a large proportion of gliomas, and pharmacological inhibition of DYRK1A by polypeptides could represent a promising therapeutic intervention for GBM.
- 26 July 2021
- Published by Wiley in Cancer Medicine
- Vol. 10 (18) , 6416-6427
Open AccessDYRK1A activates NFATC1 to increase glioblastoma migration
Glioblastoma (GBM) is the most aggressive glioma, and is prone to develop resistance to chemotherapy and radiotherapy; hence, patients with glioblastoma have a high recurrence rate and a low 1‐year survival rate. In addition, the pathogenesis of glioblastoma is complex and largely unknown, and the available treatments are limited. Here, we uncovered a fundamental role of DYRK1A in regulating NFATC1 in GBMs. We found that DYRK1A was highly expressed in glioma and glioblastoma cells, and its expression was positively correlated with that of NFATC1. Moreover, inhibition of DYRK1A promoted NFATC1 degradation in GBM cells and sharply reduced the transactivation of NFATC1, not only by decreasing the expression of NFATC1‐targeted genes, but also by reducing the luciferase activity, and vice versa. However, DYRK1A had the opposite effect on NFATC2. Most importantly, our data suggest that DYRK1A inhibition reduces glioblastoma migration. Polypeptides derived from the DYRK1A‐targeted motif of NFATC1, by competitively blocking DYRK1A kinase activity on NFATC1, clearly destabilized NFATC1 protein and impaired glioblastoma migration. We propose that the recovery of NFATC1 stability is a key oncogenic event in a large proportion of gliomas, and pharmacological inhibition of DYRK1A by polypeptides could represent a promising therapeutic intervention for GBM.